Some of the investigational therapies we are developing include nanosyringes (especially their role in delivering highly targeted cellular drug pump blockers), mitochondrial-based “smart bomb” chemotherapy and gene therapy for treatment of glioblastomas, the most common and most aggressive malignant primary brain tumor in humans.
DR. DAVID BASKIN EXPLAINS HOW A CANCEROUS GLIOMA IS TRICKED INTO TAKING IN A DAMAGING DRUG
Monoamine oxidase B (MAO-B) is a mitochondrial enzyme that is restricted to brain cells and is highly expressed in glioma. We have developed a mitochondrial “smart bomb,” a drug that is transformed by MAO-B into a form that is selectively imported into the mitochondria of the cancer cell where it attacks the mitochondrial DNA, disrupting power generation in the cell and making the cell generate harmful free radicals. This leads to the death of the cancer cell. Learn more about the Peak Center research on mitochondrial-based chemotherapy.
Read more about our ChemMedChem article
DAVID BASKIN, MD EXPLAINS HOW NANOSYRINGES CAN TARGET DRUG DELIVERY TO A SINGLE CANCER CELL
MATTHEW FUTER TALKS ABOUT HIS EXPERIENCE AT HOUSTON METHODIST
Read more about the result of the Phase 1b study in the Journal of Clinical Oncology article.
DR. DAVID BASKIN EXPLAINS HOW INSERTING A MODIFIED COLD VIRUS IN THE BRAIN CAN KILL GLIOBLASTOMA
- Initial consultation call with Peak Center specialist and referring physician
- Consistent communication throughout treatment process
- Follow up correspondence outlining the prognosis and treatment plan
- Patients will be returned to the referring physician as soon as possible